Search results for "hcv"

showing 10 items of 277 documents

One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients w…

2021

Abstract Introduction and objectives Implementation of a one-step strategy for diagnosis of active Hepatitis C virus (HCV) infection would encourage the early diagnosis and reduce the time to access antiviral treatments. The aim of this study was to evaluate the impact of a HCV one-step diagnosis compared to the traditional two-step protocol in terms of the time required for patients to be seen by specialists and the time taken to start antiviral treatment. Material and methods A comparative study was carried out to assess two diagnostic algorithms (one-step and two-step) for active HCV infection. Serological markers were quantified using the same serum sample to determine both anti-HCV ant…

MaleCare processmedicine.medical_specialtyReferralHepatitis C virusSpecialties of internal medicineViremiaHepacivirusmedicine.disease_causeAntiviral AgentsSerologyMultidisciplinary approachInterquartile rangeInternal medicineHCV-cAgmedicineTelematics referralHumansOne-stepViremiaActive hepatitisHepatologyHepatitis C virusbusiness.industryTwo-stepGeneral MedicineHepatitis C Antibodiesmedicine.diseaseHepatitis CTelemedicineRC581-951FemaleHepatitis C AntigensbusinessAnnals of hepatology
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

2017

Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child…

MaleCirrhosisSettore MED/09 - Medicina InternaAlcohol abuseAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Internal Medicinemedicine.disease_causeGastroenterology0302 clinical medicineRisk FactorsEpidemiologyHBV030212 general & internal medicineLiver Neoplasmsvirus diseasesMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver NeoplasmHepatocellular carcinomaHCV030211 gastroenterology & hepatologyAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Aged; Alcoholism; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Internal MedicineFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusLiver CirrhosiAlcohol abuseLiver cirrhosis epidemiology03 medical and health sciencesInternal medicinemedicineInternal MedicineHumansDecompensationAgedHepatitis B virusCross-Sectional Studiebusiness.industryRisk FactorCarcinomaHepatocellularmedicine.diseaseCross-Sectional StudiesLiver cirrhosisEtiologybusiness
researchProduct

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.

2014

BACKGROUND This large prospective multicentre cohort study aimed to improve knowledge of therapy for chronic hepatitis C (CHC) in real clinical practice. METHODS A diverse population of adults with CHC including patients with comorbid conditions, laboratory abnormalities and demographic features [comorbidities or special populations (CSP)] who were under-represented or excluded from peginterferon registration studies was treated with peginterferon α-2a (40 kDa) or α-2b (12 kDa) plus ribavirin at the investigator's discretion. RESULTS During the study, 5399 treatment-naive patients [2527 (46.8%) with CSP] received peginterferon α-2a (n=3513, 65.1%) or peginterferon α-2b (n=1886, 34.9%). The …

MaleCirrhosisTime FactorsComorbidityHepacivirusmedicine.disease_causePolyethylene Glycolschemistry.chemical_compoundRecurrencepeginterferonProspective Studiesspecial populationAged 80 and overbiologyRemission InductionGastroenterologyvirus diseasesMiddle AgedViral LoadRecombinant ProteinsTreatment OutcomeItalyHCVRNA ViralDrug Therapy CombinationFemalesustained virological responseCohort studyAdultcomorbiditiemedicine.medical_specialtyAdolescentGenotypeHepatitis C virusInterferon alpha-2Antiviral AgentsYoung AdultChronic hepatitisInternal medicineRibavirinmedicineHumansIn patientMedical prescriptionAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseasechemistryAlanine transaminaseImmunologybiology.proteinbusinessEuropean journal of gastroenterologyhepatology
researchProduct

Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by antiviral treatment

2006

The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e5…

MaleEpitope-specific response; HCV/E2 glycoprotein; Human monoclonal antibodies; Therapeutic responseTime FactorsSettore MED/42 - Igiene Generale e ApplicataMolecular ConformationHepacivirusmedicine.disease_causeEpitopePolyethylene GlycolsEpitopeschemistry.chemical_compoundViral Envelope ProteinsAntibody SpecificityHCV/E2 glycoproteinNeutralizing antibodyInfectivitybiologyViral Core ProteinsMiddle AgedHepatitis CEpitope-specific responseTreatment OutcomeInfectious DiseasesDisease ProgressionDrug Therapy CombinationFemaleAntibodyAdultmedicine.drug_classHepatitis C virusMonoclonal antibodyAntiviral AgentsVirusNeutralization TestsVirologyRibavirinmedicineHumansViremiaRibavirintherapeutic responseInterferon-alphaHepatitis C AntibodiesVirologyHuman monoclonal antibodieschemistryImmunologybiology.proteinhuman monoclonal antibodietope-specific response5' Untranslated Regions
researchProduct

Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER …

2021

Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both gro…

MaleHCV genotypesEthnic groupLinked-to-care patientComorbidityHepacivirusLogistic regressionmedicine.disease_causeComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patients; Aged; Antiviral Agents; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Middle Aged; Transients and MigrantsComorbidities0302 clinical medicineMedicineComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patientsChronicTransients and MigrantsCoinfectionGastroenterologyvirus diseasesMiddle AgedHepatitis CLife evaluationItaly030220 oncology & carcinogenesisLinked-to-care patientsCohort030211 gastroenterology & hepatologyFemaleComorbiditieHumanHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAAntiviral AgentsDirect acting antivirals03 medical and health sciencesDisease severityHumansAgedAntiviral AgentHepaciviruHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C Chronicmedicine.diseaseComorbiditydigestive system diseasesDirect acting antiviralHCV CohortbusinessDemography
researchProduct

Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.

2011

Background Several works observed a link between uric acid serum levels and clinical and histological features of nonalcoholic fatty liver disease. An association between chronic hepatitis C (CHC) and uric acid levels has been poorly investigated. Aims To assess the potential association between uric acid serum levels and both histological features of liver damage and sustained virological response (SVR) in a homogeneous cohort of CHC patients. Methods Consecutive biopsy-proven CHC patients were included. Hyperuricaemia was diagnosed with uric acid serum levels >7 mg/dl in men, and >6 mg/dl in women. Patients underwent therapy with pegylated interferon plus ribavirin. Results Hyperuricaemia…

MaleHCV STEATOSIS HYPERURICEMIAmedicine.medical_specialtyBiopsyRenal functionHepacivirusHyperuricemiaSettore MED/08 - Anatomia PatologicaGastroenterologychemistry.chemical_compoundPegylated interferonInternal medicineNonalcoholic fatty liver diseasemedicineHumansSettore MED/12 - GastroenterologiaHepatologybusiness.industryRibavirinHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisUric AcidFatty LiverEndocrinologychemistryUric acidFemaleSteatosisbusinessBody mass indexBiomarkersmedicine.drug
researchProduct

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.

2013

Summary We assessed, in real-life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a gender-oriented analysis, in patients with chronic hepatitis C virus (HCV) treated with pegylated interferon and ribavirin. Six hundred and seventy naive patients were treated with dual therapy and evaluated by gender and HCV genotype. Associations between baseline variables and SVR were assessed by multivariate logistic regression analysis. Among 362 genotype 1 patients, SVR was achieved in 158 patients (44%), and SVR was independently associated with age less than 50 years (OR 2.12; 95% CI 1.09–4.30; P = 0.039) and C/C genotype rs12979860…

MaleHCV-RNA levelsHepacivirusHepacivirusLogistic regressionGastroenterologyCohort Studieschemistry.chemical_compoundPegylated interferonGenotypeantiviral therapygenderProspective Studiespeg-interferon and ribavirinProspective cohort studybiologysustained virologic responsevirus diseaseschronic hepatitis C; gender; HCV-RNA levels; IL28B polymorphisms; peg-interferon and ribavirin; sustained virologic responseMiddle AgedViral LoadTreatment OutcomeInfectious DiseasesDrug Therapy CombinationFemaleViral loadHCV-RNA levels; IL28B polymorphisms; chronic hepatitis C; gender; peg-interferon and ribavirin; sustained virologic response; Adult; Aged; Cohort Studies; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Viral Loadmedicine.drugAdultmedicine.medical_specialtySex FactorsVirologyInternal medicineRibavirinmedicineHumanschronic hepatitis CRapid Virologic ResponseAgedHepatologybusiness.industryRibavirinHepatitis C Chronicbiology.organism_classificationdigestive system diseaseschemistryImmunologyInterferonsIL28B polymorphismsbusiness
researchProduct

Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors?

2012

MaleHepatologybusiness.industryHepatitis C virusGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseasemedicine.disease_causeAntiviral AgentsRecombinant ProteinsPolyethylene GlycolsInsulin resistanceChronic hepatitisDiabetes Mellitus Type 2Diabetes mellitusImmunologyRibavirininsulin resistance diabetes hcvmedicineHumansIn patientFemaleInsulin Resistancebusiness
researchProduct

Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin.

2014

Background & Aims The pool of HCV genotype 1 patients likely to be cured by peg-interferon and ribavirin remains to be quantified. Methods In 1045 patients treated with peg-interferon and ribavirin, two therapeutic strategies were confronted: the first one evaluated only baseline variables associated with sustained virological response (SVR), and the second one included the rapid virologic response (RVR) in addition to baseline predictors. An 80% SVR rate was the threshold to retain a strategy as clinically relevant. Results Overall, 414 patients (39.6%) attained SVR. In the first strategy, the hierarchy of features independently associated with SVR was IL28B CC genotype (OR 5.082; CI 3.637…

MaleIL28BChronic HCV liver diseaseHepacivirusGastroenterologyPolyethylene GlycolsVirological responseresponse predictorschemistry.chemical_compoundantiviral therapyGenotypeViralChronicchronic hepatitis C; antiviral therapy; response predictorsSettore MED/12 - Gastroenterologiavirus diseasesMiddle AgedHepatitis CRecombinant ProteinsCombinationHCVFemalePredictors of response; Ribavirin; Peg-interferon; HCV; Chronic HCV liver diseaseAdultmedicine.medical_specialtyGenotypeChronic HCV liver disease; HCV; Peg-interferon; Predictors of response; Ribavirin; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; RNA Viral; Recombinant Proteins; Ribavirin; HepatologyPredictors of responseViremiaAntiviral AgentsDrug TherapyChronic hepatitisInternal medicineRibavirinmedicinechronic hepatitis CHumansDual therapyRapid Virologic ResponseAgedgenotype 1Peg-interferonHepatologybusiness.industryRibavirinInterferon-alphamedicine.diseasedigestive system diseasesSurgeryPeg interferonPegIFNchemistryRNAbusiness
researchProduct